Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection. 2014

Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
Emory Vaccine Center at Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA. Electronic address: dbasu@emory.edu.

We have previously shown that HIV-1 superinfected Zambian seroconverters mount low binding and neutralizing antibody responses to their primary HIV-1 infecting virus, which could increase susceptibility to re-infection. Here, we investigated if antibody-dependent cellular cytotoxicity (ADCC), a process by which virus-infected cells are killed, was also reduced. Superinfected individuals exhibited low ADCC activity compared to non-superinfected individuals, but similar levels of CMV-reactive binding antibodies, suggesting superinfected individuals are capable of generating and maintaining virus-specific antibodies.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015163 Superinfection A frequent complication of drug therapy for microbial infection. It may result from opportunistic colonization following immunosuppression by the primary pathogen and can be influenced by the time interval between infections, microbial physiology, or host resistance. Experimental challenge and in vitro models are sometimes used in virulence and infectivity studies. Microbial Superinvasion,Superinvasion, Microbial,Microbial Superinvasions,Superinfections,Superinvasions, Microbial
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
September 2012, Retrovirology,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
January 2017, PloS one,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
September 2017, Journal of virology,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
November 2013, Vaccine,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
May 2022, JCI insight,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
January 1999, Methods in molecular medicine,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
February 2019, ACS infectious diseases,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
November 2014, Journal of virological methods,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
March 2011, Virology,
Debby Basu, and Peng Xiao, and Zachary Ende, and Alfred Bere, and William J Britt, and Joseph Mulenga, and William Kilembe, and Susan A Allen, and Cynthia A Derdeyn, and Eric Hunter
November 2018, AIDS (London, England),
Copied contents to your clipboard!